OSI-420 CP-473420 O-Desmethylerlotinib hydrochloride salt (also known as OSI420) is a potent drug compound that has been developed for the treatment of cancer. The chemical name of this compound is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride. Its molecular formula is C23H24N4O4.HCl, and its formula weight is 458.92 g/mol. OSI420 has a CAS number of 183320-51-6.
Top Ten Keywords from Google:
Synonyms of OSI-420 CP-473420 O-Desmethylerlotinib hydrochloride salt include OSI420, CP-473420, O-DMEL, and N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride.
Health Benefits of OSI-420 CP-473420 O-Desmethylerlotinib hydrochloride salt:
OSI420 is a small molecule drug that functions as an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a protein that plays a key role in the development and progression of many types of cancer. By inhibiting EGFR, OSI420 blocks the signaling pathways that promote tumor growth and survival. This results in a decrease in cell proliferation, increased apoptosis, and decreased angiogenesis.
Potential Effects of OSI-420 CP-473420 O-Desmethylerlotinib hydrochloride salt:
In preclinical studies, OSI420 has demonstrated potent anti-tumor activity against a variety of different cancer cell lines, including non-small cell lung cancer, pancreatic cancer, prostate cancer, and breast cancer. In addition, OSI420 has been shown to be effective in both in vitro and in vivo models of cancer, indicating that it may have therapeutic potential in human patients.
Product Mechanism:
OSI420 works by specifically targeting and inhibiting the activity of EGFR. This protein is overexpressed in many types of cancer and plays a critical role in promoting tumor growth and survival. By blocking EGFR, OSI420 disrupts the signaling pathways that are essential for cancer cell proliferation and survival. This leads to decreased tumor growth and increased apoptosis.
Safety of OSI-420 CP-473420 O-Desmethylerlotinib hydrochloride salt:
Like all drugs, OSI420 can have side effects. However, the safety profile of OSI420 appears to be favorable based on data from preclinical studies. In these studies, mice were given high doses of OSI420 for extended periods of time without experiencing significant toxicity or adverse events. Further studies are needed to determine the long-term safety and efficacy of OSI420 in human patients.
Side Effects of OSI-420 CP-473420 O-Desmethylerlotinib hydrochloride salt:
The most common side effects of OSI420 are fatigue, nausea, vomiting, and diarrhea. In addition, some patients may experience skin rash, itching, or dryness. These side effects are generally mild to moderate in severity and can usually be managed with supportive care. Rarely, more serious side effects may occur, such as liver toxicity, cardiac toxicity, or interstitial lung disease. If you experience any of these symptoms while taking OSI420, you should contact your doctor immediately.
Dosing Information:
The optimal dose of OSI420 for human patients has not yet been established. Clinical trials are currently underway to evaluate the safety and efficacy of OSI420 in patients with advanced solid tumors. As with all medications, it is important to follow your doctor's instructions regarding dosing and administration of OSI420.
Conclusion:
OSI-420 CP-473420 O-Desmethylerlotinib hydrochloride salt is a promising new small molecule drug that shows potential for the treatment of various types of cancer. Its mechanism of action, which involves inhibition of EGFR, makes it a promising candidate for molecular targeted therapy. While more research is needed to establish its safety and efficacy in human patients, preclinical studies suggest that OSI420 may have significant anti-tumor activity and could ultimately offer new hope for patients with cancer.
